Doctors at Rush University Medical Center are offering pediatric patients diagnosed with chronic illnesses acupuncture therapy to help ease the pain and negative side effects like nausea, fatigue, and vomiting caused by chronic health conditions and intensive treatments. The confluence of Chinese and Western medicine at Rush Children's Hospital is part of a study to analyze and document how acupuncture might help in reducing pain in children and increase quality of life. "Treating children with acupuncture is a new frontier, " said Dr. Paul Kent, pediatric hematology and oncology expert, Rush Children's Hospital. "We are looking to see if there is an effective pain management therapy we can offer that does not have the serious side effects that can be caused by narcotics and other serious pain medications." The lack of options for pain management in children has been reported as one of the most difficult aspects of providing care to pediatric patients. Research indicates that up to 70 percent of pediatric patients experience pain and those with chronic illnesses often do not have adequate relief or prevention of pain.
Australian general practitioners often treat patients with low back pain in a manner that does not appear to match the care endorsed by international clinical guidelines, according to a report in the February 8 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. Low back pain is estimated to be the seventh most common reason for a general practitioner visit in Australia and the fifth most common in the United States, according to background information in the article. An overwhelming body of literature on the management of low back pain-more than 1, 200 published trials and systematic reviews-makes practice guidelines an efficient way for clinicians to base their care on the best evidence. A previous review concluded that guidelines in 11 countries around the world provide similar recommendations for assessment and management of low back pain. "Given the proliferation of clinical practice guidelines outlining best practice, it is timely to consider how closely usual care aligns with guideline recommendations, " write Christopher M.
Amneal Pharmaceuticals is pleased to announce that it received U.S. FDA approval to manufacture combination Tramadol HCl in 37.5 mg strength and Acetaminophen in 325 mg strength (Tramadol/APAP) in tablet form effective December 9, 2009. Amneal's generic is an AB-rated, therapeutically equivalent alternative to Ultracet ® (a licensed trademark of Ortho-McNeil Janssen). U.S. sales of Tramadol/APAP were $61 MM according to June 2009 IMS Health market data. Tramadol/APAP is a centrally-acting analgesic indicated for the short-term management of moderately severe acute pain. The product is designated a controlled substance in some states. Amneal began shipping Tramadol/APAP in 100-, 500- and 1000-count sizes on January 25, 2010. It will be available through wholesalers-distributors as well as directly to the trade. The oral solid is manufactured in the company's cGMP-compliant Hauppauge, NY production facility. Amneal manufactures all of its own products in the USA. "Tramadol/APAP is a logical extension of our well-established Tramadol line, which enjoys a solid market share in the industry, " said Jim Luce, Amneal Executive Vice President, Sales & Marketing.
Fewer than half of individuals who have "non-specific" chest pain (not explained by a well-known condition) experience relief from symptoms following standard medical care, according to a report in the February 8 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. In addition, one-tenth of those with persistent chest pain undergo potentially unnecessary diagnostic testing. More than half of patients with chest pain are classified as not having an underlying heart condition, according to background information in the article. Some have another well-established medical condition, such as upper respiratory tract infection, but for many no pathophysiologic cause can be found. Such non-specific chest pain "is a frequent phenomenon in primary care, " the authors write. "However, knowledge about the course and outcome of this condition is sparse." Julia Anna Glombiewski, Ph.D., of Philipps-University of Marburg, Germany, and colleagues studied 807 patients (average age 57.
In a unique and comprehensive literature review of poisoning deaths involving opioids from 1999 -- 2009, the deaths involving methadone were found to be disproportionately high. Methadone represented less than five percent of all opioid prescriptions but is responsible for a third of the deaths. After four years of investigation, the major underlying cause was found to be fundamental misunderstandings about the properties of the medicine -- a "knowledge deficit" -- especially when converting patients from other opioids. The results of the literature review, root causes of the increase in poisoning deaths during this time period, and suggested solutions to this issue were presented at the American Academy of Pain Medicine's 26th Annual Meeting. After a rapid increase of opioid-related deaths was reported in Utah, then president of the Utah Academy of Pain Medicine, Dr. Lynn Webster decided to find out why, and then find a solution. By reviewing state and federal sources as well as PubMed, he was able to assess demographics, prevalence, and other risk factors related to this significant increase in poisoning deaths involving opioids.
Addex Pharmaceuticals / Addex: ADX71943 Demonstrates Analgesic Effects in Pain Models processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. Addex Pharmaceuticals (SWISS: ADXN), the allosteric modulation company, announced today that ADX71943 has demonstrated statistically significant analgesic-like effects in three preclinical models of pain. In the first model, ADX71943 reversed complete Freund adjuvant (CFA)- induced reductions in withdrawal thresholds in a dose-related manner, with a minimum statistically significant effective oral dose of 10 mg/kg. In a second model (Formalin test), ADX71943 showed anti-nociceptive effect after oral administration of 3 to 10 mg/kg. In a third model, an increased visceral pain threshold was seen using ADX71943 with a minimum statistically significant effective dose between 3 and 10 mg/kg. ADX71943 is an orally available positive allosteric modulator (PAM) of the GABA(B) receptor that has potential for treatment of osteoarthritis pain and chronic nociceptive pain as well as other indications.
Differences might exist in the amount of pain medicine given to Latino and white children after surgery, found a new, small study in which Latino children received 30 percent less opioid analgesics (morphine or morphine-like drugs) than white children did. During surgery, administration of non-opioid analgesics (such as acetaminophen) and opioid analgesics was similar between Latino and white children, said lead study author Nathalia Jimenez, M.D., of Seattle Children's Hospital. However, the significant difference after surgery suggests that pain treatment in children has some correlation with the patient's ethnicity, according to the authors. "The population in the United States is changing. Twenty-five percent of all the kids are Latino, " Jimenez said. "This is a little window to see how different people are treated or react differently to pain." The study, which appears in the February issue of the Journal of Health Care for the Poor and Underserved, compared the anesthetic and recovery period records of Latino and white children who had tonsillectomy and adenoidectomy surgery at Seattle Children's Hospital between 2003 and 2005.
Cara Therapeutics Reports Positive Phase II Data For Novel Peripheral Analgesic In Acute Post-Operative Pain
Cara Therapeutics, Inc. announced positive data in a Phase II proof-of-concept clinical trial of its peripherally-restricted kappa opioid agonist, CR845. The 46 patient Phase II, multi-center, double-blind, placebo-controlled study was conducted at eight hospitals in the United States and evaluated the efficacy and safety of CR845 in women following laparoscopic-assisted hysterectomy. Subjects were administered a single intravenous infusion of 0.040 mg/kg CR845 or placebo following surgery, upon reporting a moderate-to-severe pain intensity level of 5 to 8 on a 0-10 pain scale. Analgesia was first assessed by pain intensity measurements for up to 8 hours post-infusion or until the patient requested morphine by initiation of patient-controlled analgesia (PCA morphine). Subsequently, analgesia was assessed by the amount of morphine required to alleviate pain until 16 hrs after drug administration. Significant pain relief was observed in CR845-treated patients over placebo from 4-8 hrs post-drug administration, as exemplified by a significant change in pain intensity difference (PID) scores (p<0.
The U.S. Food and Drug Administration approved Morphine Sulfate Oral Solution for the relief of moderate to severe, acute and chronic pain in opioid-tolerant patients. This medicine will be available in 100 milligrams per 5 mL or 20 milligrams per 1 mL. This is the only FDA-approved morphine sulfate oral solution available at this concentration. Although the use of this medicine to manage pain has been common practice for many years, this form and concentration of morphine was not FDA-approved until now. Today's action is part of the FDA's unapproved drugs initiative. As part of this program, the FDA has worked with the manufacturer of the now-approved product, Roxane Laboratories, to ensure that there is enough drug available for patients. The FDA will also be working with patient organizations and prescribers so that they are aware that an approved product is available, and can notify the FDA if there are any problems with availability. "An important goal of the unapproved drugs initiative is to make sure that marketed drugs meet current FDA standards, " said Douglas Throckmorton, M.
New, Targeted Pain Medicine Delivery Systems May Reduce Costs Long Term; Cost To Treat Pain Varies Significantly By Chronic Pain Condition
Estimates of pain care treatment costs exceed $1 billion annually in the United States. Today at the American Academy of Pain Medicine's 26th Annual Meeting two abstracts looked at the issue. One evaluated intrathecal drug delivery (a targeted medicine delivery system) that could save costs over time. The other analyzed the differences between the costs of treatment for chronic pain treatments. In the first abstract, Scott Guillemette from Ingenix Consulting analyzed costs for intrathecal drug delivery (IDD). The implantable neuromodulatory device, which delivers medicine directly to the spinal cord, was used to treat pain patients suffering from Failed Back Surgery Syndrome (FBSS). The results of the analysis suggest that patients utilizing IDD moved closer to a normal lifestyle more quickly than patients on conventional therapy such as oral medicines, or physical therapy. This was found to correlate to lower future medical costs, such as doctor visits and additional intervention.